دورية أكاديمية
أعرض في EDS

Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New Zealand.

التفاصيل البيبلوغرافية
العنوان: Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New Zealand.
المؤلفون: Claflin S; Menzies Institute for Medical Research, University of Tasmania, Medical Science Precinct, 17 Liverpool Street, Hobart, TAS, 7000, Australia. Suzi.Claflin@utas.edu.au., Campbell JA; Menzies Institute for Medical Research, University of Tasmania, Medical Science Precinct, 17 Liverpool Street, Hobart, TAS, 7000, Australia. Julie.Campbell@utas.edu.au., Norman R; Curtin University, Perth, Australia., Mason DF; New Zealand Brain Research Institute, Christchurch, New Zealand., Kalincik T; CORe The University of Melbourne, Melbourne, Australia.; Department of Neurology, The Royal Melbourne Hospital, Melbourne, Australia., Simpson-Yap S; Menzies Institute for Medical Research, University of Tasmania, Medical Science Precinct, 17 Liverpool Street, Hobart, TAS, 7000, Australia.; Neuroepidemiology Unit, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia., Butzkueven H; Department of Neuroscience, Monash University, Melbourne, Australia., Carroll WM; Perron Institute, Nedlands, Australia., Palmer AJ; Menzies Institute for Medical Research, University of Tasmania, Medical Science Precinct, 17 Liverpool Street, Hobart, TAS, 7000, Australia.; Centre for Health Policy, School of Population and Global Health, The University of Melbourne, Melbourne, Australia., Blizzard CL; Menzies Institute for Medical Research, University of Tasmania, Medical Science Precinct, 17 Liverpool Street, Hobart, TAS, 7000, Australia., van der Mei I; Menzies Institute for Medical Research, University of Tasmania, Medical Science Precinct, 17 Liverpool Street, Hobart, TAS, 7000, Australia., Henson GJ; Menzies Institute for Medical Research, University of Tasmania, Medical Science Precinct, 17 Liverpool Street, Hobart, TAS, 7000, Australia., Taylor BV; Menzies Institute for Medical Research, University of Tasmania, Medical Science Precinct, 17 Liverpool Street, Hobart, TAS, 7000, Australia. Bruce.Taylor@utas.edu.au.
المصدر: The European journal of health economics : HEPAC : health economics in prevention and care [Eur J Health Econ] 2023 Aug; Vol. 24 (6), pp. 939-950. Date of Electronic Publication: 2022 Sep 23.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer-Verlag Country of Publication: Germany NLM ID: 101134867 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1618-7601 (Electronic) Linking ISSN: 16187598 NLM ISO Abbreviation: Eur J Health Econ Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Berlin : Springer-Verlag, c2001-
مواضيع طبية MeSH: Multiple Sclerosis*/drug therapy, Humans ; Female ; Middle Aged ; Male ; Australia/epidemiology ; New Zealand/epidemiology ; Quality of Life ; Policy ; Surveys and Questionnaires ; Health Status
مستخلص: Background: Health state utilities (HSU) are a health-related quality-of-life (HRQoL) input for cost-utility analyses used for resource allocation decisions, including medication reimbursement. New Zealand (NZ) guidelines recommend the EQ-5D instruments; however, the EQ-5D-5L may not sufficiently capture psychosocial health. We evaluated HRQoL among people with multiple sclerosis (MS) in NZ using the EQ-5D-5L and assessed the instrument's discriminatory sensitivity for a NZ MS cohort.
Methods: Participants were recruited from the NZ MS Prevalence Study. Participants self-completed a 45-min online survey that included the EQ-5D-5L/EQ-VAS. Disability severity was classified using the Expanded Disability Status Scale (EDSS) to categorise participant disability as mild (EDSS: 0-3.5), moderate (EDSS: 4.0-6.0) and severe (EDSS: 6.5-9.5). Anxiety/depression were also measured using the Hospital Anxiety and Depression Score (HADS). In the absence of an EQ-5D-5L NZ tariff, HSUs were derived using an Australian tariff. We evaluated associations between HSUs and participant characteristics with linear regression models.
Results: 254 participants entered the study. Mean age was 55.2 years, 79.5% were female. Mean (SD) EQ-5D-5L HSU was 0.58 (0.33). Mean (SD) HSUs for disability categories were: mild 0.80 ± 0.17, moderate 0.57 ± 0.21 and severe 0.14 ± 0.32. Twelve percent reported HSU = 1.0 (i.e., no problems in any domain). Participants who had never used a disease-modifying therapy reported a lower mean HSU. Multivariable modelling found that the HADS anxiety score was not associated with EQ-5D-5L.
Conclusions: HRQoL for people with MS in NZ was lower than comparable countries, including Australia. We suggest a comparison with other generic tools that may have improved sensitivity to mental health.
(© 2022. The Author(s).)
References: Neuroepidemiology. 2014;42(3):154-60. (PMID: 24556851)
Patient. 2016 Aug;9(4):311-22. (PMID: 26841910)
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95. (PMID: 12900694)
Qual Life Res. 2011 Dec;20(10):1727-36. (PMID: 21479777)
Health Qual Life Outcomes. 2014 Feb 18;12:21. (PMID: 24548314)
Mult Scler. 2021 Jul;27(8):1262-1275. (PMID: 32924841)
N Z Med J. 2000 Dec 8;113(1123):517-20. (PMID: 11198514)
Mult Scler. 2020 Oct;26(12):1550-1559. (PMID: 33063620)
Mult Scler. 2020 Oct;26(11):1315-1328. (PMID: 31347952)
Eur J Neurol. 2019 Jan;26(1):155-161. (PMID: 30133059)
Qual Life Res. 2015 Aug;24(8):2045-53. (PMID: 25636660)
Health Econ. 2014 Jun;23(6):729-42. (PMID: 23765787)
J Neurol. 2013 Oct;260(10):2505-10. (PMID: 23807152)
Mult Scler. 2010 Dec;16(12):1422-31. (PMID: 20813774)
Crit Care Resusc. 2013 Sep;15(3):205-12. (PMID: 23944207)
Mult Scler Relat Disord. 2018 Feb;20:9-15. (PMID: 29274564)
Health Econ. 2004 Sep;13(9):873-84. (PMID: 15362179)
Qual Life Res. 2020 Nov;29(11):3119-3129. (PMID: 32648198)
Value Health. 2017 Apr;20(4):644-650. (PMID: 28408007)
Health Qual Life Outcomes. 2016 Sep 20;14(1):133. (PMID: 27644755)
Value Health. 2021 Sep;24(9):1308-1318. (PMID: 34452711)
Pharmacoeconomics. 2014 Aug;32(8):759-73. (PMID: 24846760)
Med Decis Making. 2015 Apr;35(3):276-91. (PMID: 25159172)
Appl Health Econ Health Policy. 2013 Jun;11(3):287-98. (PMID: 23649892)
Eur J Health Econ. 2020 Nov;21(8):1245-1257. (PMID: 32514643)
Mult Scler. 2019 Jun;25(7):994-1004. (PMID: 29911469)
Mult Scler. 2022 Apr;28(5):831-841. (PMID: 34387513)
Neurology. 2005 Apr 12;64(7):1144-51. (PMID: 15824338)
J Neurol Sci. 2013 Aug 15;331(1-2):102-7. (PMID: 23791482)
Intensive Care Med. 2020 Sep;46(9):1696-1706. (PMID: 32676679)
Med Care. 2009 Jan;47(1):61-8. (PMID: 19106732)
Appl Health Econ Health Policy. 2017 Apr;15(2):127-137. (PMID: 28194657)
Mult Scler. 2017 Jul;23(8):1157-1166. (PMID: 27698247)
Pharmacoecon Open. 2018 Dec;2(4):443-458. (PMID: 29623636)
Qual Life Res. 2020 Sep;29(9):2509-2527. (PMID: 32488685)
World J Surg. 2019 Jun;43(6):1554-1562. (PMID: 30719557)
فهرسة مساهمة: Keywords: Cost-effectiveness analysis; Cost-utility analysis; Health technology assessment; Multi-attribute utility instrument; Quality of life
تواريخ الأحداث: Date Created: 20220923 Date Completed: 20230626 Latest Revision: 20230701
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC10290609
DOI: 10.1007/s10198-022-01518-x
PMID: 36149605
قاعدة البيانات: MEDLINE
الوصف
تدمد:1618-7601
DOI:10.1007/s10198-022-01518-x